DRUG-CLASS OVERVIEW:@0.982174:0.513429:0.982174:0.311367:0.954164:0.311367:0.954164:0.513429:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.233372:0.041064:0.000000:0.000000:0.019473
189:@0.945393:0.038601:0.984904:0.038601:0.984904:0.019004:0.945393:0.019004:0.013170:0.013170:0.013170
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
n :@0.084848:0.076380:0.098177:0.076380:0.098177:0.067940:0.084848:0.067940:0.009762:0.003566
 :@0.115149:0.076380:0.118715:0.076380:0.118715:0.067940:0.115149:0.067940:0.003566
Gastric cancer:@0.115151:0.079499:0.254563:0.079499:0.254563:0.063743:0.115151:0.063743:0.016779:0.013143:0.007466:0.006523:0.005792:0.003848:0.012450:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792
 :@0.084845:0.094937:0.090175:0.094937:0.090175:0.079182:0.084845:0.079182:0.005330
 –   recurrent locally advanced or :@0.115148:0.094937:0.429869:0.094937:0.429869:0.079182:0.115148:0.079182:0.000000:0.009621:0.005330:0.015352:0.000000:0.005713:0.012508:0.012450:0.011699:0.005792:0.005705:0.012508:0.011738:0.006523:0.005330:0.003848:0.012604:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.005330:0.012604:0.005792:0.005330
metastatic gastric or gastro-:@0.145458:0.110376:0.406963:0.110376:0.406963:0.094620:0.145458:0.094620:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.012950:0.013143:0.007466:0.006523:0.005792:0.003848:0.012450:0.005330:0.012604:0.005792:0.005330:0.012950:0.013143:0.007466:0.006523:0.005696:0.012604:0.006388
oesophageal junction :@0.145458:0.125814:0.356259:0.125814:0.356259:0.110058:0.145458:0.110058:0.012604:0.012508:0.007466:0.012604:0.013123:0.011738:0.013143:0.012950:0.012508:0.013143:0.003848:0.005330:0.003906:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330
adenocarcinoma whose tumours :@0.145458:0.141253:0.461836:0.141253:0.461836:0.125497:0.145458:0.125497:0.013143:0.013181:0.012508:0.011738:0.012604:0.012450:0.013143:0.005651:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.015990:0.011738:0.012604:0.007466:0.012508:0.005330:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330
express PD-L1 [Combined Positive :@0.145458:0.156691:0.462744:0.156691:0.462744:0.140935:0.145458:0.140935:0.012508:0.009236:0.013123:0.005713:0.012508:0.007466:0.007466:0.005330:0.011392:0.014316:0.006388:0.008890:0.010660:0.005330:0.006754:0.015644:0.012604:0.018049:0.013123:0.003848:0.011738:0.012508:0.013181:0.005330:0.011392:0.012604:0.007466:0.003848:0.006523:0.003848:0.010660:0.012508:0.005330
Score (CPS) ≥1], with disease :@0.145458:0.172130:0.417309:0.172130:0.417309:0.156374:0.145458:0.156374:0.009583:0.012450:0.012604:0.005709:0.012508:0.005330:0.007100:0.015644:0.011392:0.009583:0.007100:0.005330:0.010564:0.010660:0.006754:0.005330:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330
progression on or after two or more :@0.145458:0.187568:0.477573:0.187568:0.477573:0.171812:0.145458:0.171812:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.012604:0.011738:0.005330:0.012604:0.005792:0.005330:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330:0.006523:0.015990:0.012604:0.005330:0.012604:0.005792:0.005330:0.018049:0.012604:0.005657:0.012508:0.005330
prior lines of therapy, including :@0.145458:0.203007:0.435095:0.203007:0.435095:0.187251:0.145458:0.187251:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330:0.003848:0.003848:0.011738:0.012508:0.007466:0.005330:0.012604:0.006042:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.005330
fluoropyrimidine- and platinum-:@0.145458:0.218445:0.437123:0.218445:0.437123:0.202689:0.145458:0.202689:0.004666:0.004666:0.011699:0.012604:0.005703:0.012604:0.013123:0.010314:0.005792:0.003848:0.018049:0.003848:0.013181:0.003848:0.011738:0.012508:0.006388:0.005330:0.013143:0.011738:0.013181:0.005330:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388
containing chemotherapy and if :@0.145458:0.233883:0.455800:0.233883:0.455800:0.218127:0.145458:0.218127:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.013143:0.011738:0.013181:0.005330:0.003848:0.006042:0.005330
appropriate, HER2/neu-targeted :@0.145458:0.249322:0.453764:0.249322:0.453764:0.233566:0.145458:0.233566:0.013143:0.013123:0.013123:0.005719:0.012604:0.013123:0.005792:0.003848:0.013143:0.006523:0.012508:0.005330:0.005330:0.013143:0.010314:0.011680:0.010660:0.008409:0.011738:0.012508:0.011699:0.006388:0.006523:0.013143:0.005792:0.012950:0.012508:0.006523:0.012508:0.013181:0.005330
therapy:@0.145458:0.264760:0.218599:0.264760:0.218599:0.249004:0.145458:0.249004:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
Nivolumab:@0.084848:0.295150:0.197737:0.295150:0.197737:0.277129:0.084848:0.277129:0.015822:0.005131:0.011973:0.013683:0.005131:0.012828:0.020098:0.014111:0.014111
Nivolumab is indicated for the treatment :@0.084848:0.313210:0.481090:0.313210:0.481090:0.297454:0.084848:0.297454:0.014239:0.003848:0.010660:0.012604:0.003848:0.011699:0.018049:0.013143:0.013123:0.007909:0.003848:0.007466:0.007909:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.007909:0.006042:0.012604:0.005792:0.007897:0.006523:0.011738:0.012508:0.007909:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
of::@0.084848:0.328648:0.108824:0.328648:0.108824:0.312893:0.084848:0.312893:0.012604:0.006042:0.005330
133 :@0.108817:0.323035:0.130569:0.323035:0.130569:0.313849:0.108817:0.313849:0.006215:0.006215:0.006215:0.003107
n :@0.084848:0.341566:0.098177:0.341566:0.098177:0.333126:0.084848:0.333126:0.009762:0.003566
 :@0.115149:0.341566:0.118715:0.341566:0.118715:0.333126:0.115149:0.333126:0.003566
BRAF V600 wild-type unresectable or :@0.115151:0.344685:0.460930:0.344685:0.460930:0.328929:0.115151:0.328929:0.011045:0.011680:0.014239:0.009333:0.005330:0.013508:0.010660:0.010660:0.010660:0.005330:0.015990:0.003848:0.003848:0.013181:0.006388:0.006523:0.010314:0.013123:0.012508:0.005330:0.011699:0.011738:0.005707:0.012508:0.007466:0.012508:0.012450:0.006523:0.013143:0.013123:0.003848:0.012508:0.005330:0.012604:0.005792:0.005330
metastatic melanoma, as a single :@0.115151:0.360123:0.436500:0.360123:0.436500:0.344368:0.115151:0.344368:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.018049:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143:0.005330:0.005330:0.013143:0.007466:0.005330:0.013143:0.005330:0.007466:0.003848:0.011738:0.012950:0.003848:0.012508:0.005330
agent:@0.115151:0.375562:0.172013:0.375562:0.172013:0.359806:0.115151:0.359806:0.013143:0.012950:0.012508:0.011738:0.006523
n :@0.084848:0.388485:0.098177:0.388485:0.098177:0.380044:0.084848:0.380044:0.009762:0.003566
 :@0.115149:0.388485:0.118715:0.388485:0.118715:0.380044:0.115149:0.380044:0.003566
BRAF V600 mutation-positive unresect-:@0.115151:0.391604:0.471015:0.391604:0.471015:0.375848:0.115151:0.375848:0.011045:0.011680:0.014239:0.009333:0.005330:0.013508:0.010660:0.010660:0.010660:0.005330:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.006388:0.013123:0.012604:0.007466:0.003848:0.006523:0.003848:0.010660:0.012508:0.005330:0.011699:0.011738:0.005709:0.012508:0.007466:0.012508:0.012450:0.006523:0.006388
able or metastatic melanoma, as a :@0.115151:0.407042:0.450489:0.407042:0.450489:0.391286:0.115151:0.391286:0.013143:0.013123:0.003848:0.012508:0.005330:0.012604:0.005792:0.005330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.018049:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143:0.005330:0.005330:0.013143:0.007466:0.005330:0.013143:0.005330
single agent:@0.115151:0.422481:0.229702:0.422481:0.229702:0.406725:0.115151:0.406725:0.007466:0.003848:0.011738:0.012950:0.003848:0.012508:0.005330:0.013143:0.012950:0.012508:0.011738:0.006523
n :@0.084848:0.435403:0.098177:0.435403:0.098177:0.426963:0.084848:0.426963:0.009762:0.003566
 :@0.115149:0.435403:0.118715:0.435403:0.118715:0.426963:0.115149:0.426963:0.003566
unresectable or metastatic melano-:@0.115151:0.438522:0.451216:0.438522:0.451216:0.422766:0.115151:0.422766:0.011699:0.011738:0.005711:0.012508:0.007466:0.012508:0.012450:0.006523:0.013143:0.013123:0.003848:0.012508:0.005330:0.012604:0.005792:0.005330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.018049:0.012508:0.003848:0.013143:0.011738:0.012604:0.006388
ma, in combination with ipilimumab:@0.115151:0.453961:0.448930:0.453961:0.448930:0.438205:0.115151:0.438205:0.018049:0.013143:0.005330:0.005330:0.003848:0.011738:0.005330:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.003848:0.013123:0.003848:0.003848:0.003848:0.018049:0.011699:0.018049:0.013143:0.013123
n :@0.084848:0.466878:0.098177:0.466878:0.098177:0.458438:0.084848:0.458438:0.009762:0.003566
 :@0.115149:0.466878:0.118715:0.466878:0.118715:0.458438:0.115149:0.458438:0.003566
melanoma with lymph-node involve-:@0.115151:0.469997:0.458070:0.469997:0.458070:0.454241:0.115151:0.454241:0.018049:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.003848:0.010314:0.018049:0.013123:0.011738:0.006388:0.011738:0.012604:0.013181:0.012508:0.005330:0.003848:0.011738:0.010660:0.012604:0.003848:0.010660:0.012508:0.006388
ment or metastatic disease who have :@0.115151:0.485436:0.473022:0.485436:0.473022:0.469680:0.115151:0.469680:0.018049:0.012508:0.011738:0.006523:0.005330:0.012604:0.005792:0.005330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.015990:0.011738:0.012604:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330
undergone complete resection, in the :@0.115151:0.500874:0.475152:0.500874:0.475152:0.485118:0.115151:0.485118:0.011699:0.011738:0.013181:0.012508:0.005792:0.012950:0.012604:0.011738:0.012508:0.005330:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.006523:0.012508:0.005330:0.005690:0.012508:0.007466:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330:0.003848:0.011738:0.005330:0.006523:0.011738:0.012508:0.005330
adjuvant setting:@0.115151:0.516313:0.266031:0.516313:0.266031:0.500557:0.115151:0.500557:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950
n :@0.084848:0.529240:0.098177:0.529240:0.098177:0.520800:0.084848:0.520800:0.009762:0.003566
 :@0.115149:0.529240:0.118715:0.529240:0.118715:0.520800:0.115149:0.520800:0.003566
metastatic non-small-cell lung cancer :@0.115151:0.532360:0.472849:0.532360:0.472849:0.516604:0.115151:0.516604:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.011738:0.012604:0.011738:0.006388:0.007466:0.018049:0.013143:0.003848:0.003848:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330:0.003848:0.011719:0.011738:0.012950:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330
and progression on or after platinum-:@0.115151:0.547798:0.460695:0.547798:0.460695:0.532042:0.115151:0.532042:0.013143:0.011738:0.013181:0.005330:0.013123:0.005713:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.012604:0.011738:0.005330:0.012604:0.005792:0.005330:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388
based chemotherapy. EGFR or ALK :@0.115151:0.563236:0.448045:0.563236:0.448045:0.547481:0.115151:0.547481:0.013123:0.013143:0.007466:0.012508:0.013181:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.010314:0.016779:0.009333:0.011680:0.005330:0.012604:0.005792:0.005330:0.014239:0.008890:0.011372:0.005330
genomic tumour aberrations should :@0.115151:0.578675:0.453202:0.578675:0.453202:0.562919:0.115151:0.562919:0.012950:0.012508:0.011738:0.012604:0.018049:0.003848:0.012450:0.005330:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005330:0.013143:0.013123:0.012508:0.005792:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.005330
have disease progression:@0.115151:0.594113:0.349713:0.594113:0.349713:0.578357:0.115151:0.578357:0.011738:0.013143:0.010660:0.012508:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.013123:0.005721:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738
n :@0.084848:0.607046:0.098177:0.607046:0.098177:0.598606:0.084848:0.598606:0.009762:0.003566
 :@0.115149:0.607046:0.118715:0.607046:0.118715:0.598606:0.115149:0.598606:0.003566
advanced renal cell carcinoma in :@0.115151:0.610165:0.440075:0.610165:0.440075:0.594409:0.115151:0.594409:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.005330:0.005707:0.012508:0.011738:0.013143:0.003848:0.005330:0.012450:0.012508:0.003848:0.003848:0.005330:0.012450:0.013143:0.005661:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.003848:0.011738:0.005330
patients who have received prior :@0.115151:0.625604:0.429578:0.625604:0.429578:0.609848:0.115151:0.609848:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.011738:0.012604:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330:0.005702:0.012508:0.012450:0.012508:0.003848:0.010660:0.012508:0.013181:0.005330:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330
antiangiogenic therapy:@0.115151:0.641042:0.336651:0.641042:0.336651:0.625286:0.115151:0.625286:0.013143:0.011738:0.006523:0.003848:0.013143:0.011738:0.012950:0.003848:0.012604:0.012950:0.012508:0.011738:0.003848:0.012450:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
n :@0.084848:0.653965:0.098177:0.653965:0.098177:0.645524:0.084848:0.645524:0.009762:0.003566
 :@0.115149:0.653965:0.118715:0.653965:0.118715:0.645524:0.115149:0.645524:0.003566
adult patients with classical Hodgkin’s :@0.115151:0.657084:0.472189:0.657084:0.472189:0.641328:0.115151:0.641328:0.013143:0.013181:0.011699:0.003848:0.006523:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.012450:0.003848:0.013143:0.007466:0.007466:0.003848:0.012450:0.013156:0.003848:0.005330:0.013143:0.012604:0.013181:0.012950:0.009660:0.003848:0.011738:0.006754:0.007466:0.005330
lymphoma that has relapsed or :@0.115151:0.672522:0.412822:0.672522:0.412822:0.656766:0.115151:0.656766:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.005330:0.006523:0.011738:0.013143:0.006523:0.005330:0.011738:0.013143:0.007466:0.005330:0.005705:0.012508:0.003848:0.013143:0.013123:0.007466:0.012508:0.013181:0.005330:0.012604:0.005792:0.005330
progressed after::@0.115151:0.687961:0.273045:0.687961:0.273045:0.672205:0.115151:0.672205:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.005330:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330
 :@0.084845:0.703399:0.090175:0.703399:0.090175:0.687643:0.084845:0.687643:0.005330
  –   autologous haematopoietic :@0.115148:0.703399:0.413836:0.703399:0.413836:0.687643:0.115148:0.687643:0.005330:-0.005330:0.009621:0.005330:0.015352:0.000000:0.013143:0.011699:0.006523:0.012604:0.003848:0.012604:0.012950:0.012588:0.011699:0.007466:0.005328:0.011738:0.013143:0.012508:0.018049:0.013143:0.006523:0.012604:0.013123:0.012594:0.003848:0.012508:0.006523:0.003848:0.012450:0.005330
stem-cell transplantation (HSCT) :@0.145458:0.718838:0.446698:0.718838:0.446698:0.703082:0.145458:0.703082:0.007466:0.006523:0.012508:0.018049:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330:0.006523:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.007100:0.013143:0.009583:0.015644:0.008197:0.007100:0.005330
and brentuximab vedotin, or:@0.145458:0.734276:0.413003:0.734276:0.413003:0.718520:0.145458:0.718520:0.013143:0.011738:0.013181:0.005330:0.013123:0.005713:0.012508:0.011738:0.006523:0.011699:0.009236:0.003848:0.018049:0.013143:0.013123:0.005330:0.010660:0.012508:0.013181:0.012604:0.006523:0.003848:0.011738:0.005330:0.005330:0.012604:0.005792
 :@0.084845:0.749714:0.090175:0.749714:0.090175:0.733959:0.084845:0.733959:0.005330
 –   three or more lines of systemic :@0.115148:0.749714:0.430354:0.749714:0.430354:0.733959:0.115148:0.733959:0.000000:0.009621:0.005330:0.015352:0.000000:0.006523:0.011738:0.005713:0.012508:0.012508:0.005330:0.012604:0.005792:0.005313:0.018049:0.012604:0.005707:0.012508:0.005330:0.003848:0.003848:0.011738:0.012508:0.007466:0.005330:0.012604:0.006042:0.005330:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.003848:0.012450:0.005330
therapy that includes autologous :@0.145458:0.765153:0.459725:0.765153:0.459725:0.749397:0.145458:0.749397:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.006523:0.011738:0.013143:0.006523:0.005330:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.007466:0.005330:0.013143:0.011699:0.006523:0.012604:0.003848:0.012604:0.012950:0.012604:0.011699:0.007466:0.005330
HSCT:@0.145458:0.780591:0.192025:0.780591:0.192025:0.764835:0.145458:0.764835:0.013143:0.009583:0.015644:0.008197
n :@0.084848:0.793545:0.098177:0.793545:0.098177:0.785104:0.084848:0.785104:0.009762:0.003566
 :@0.115149:0.793545:0.118715:0.793545:0.118715:0.785104:0.115149:0.785104:0.003566
recurrent or metastatic squamous cell :@0.115151:0.796664:0.472899:0.796664:0.472899:0.780908:0.115151:0.780908:0.005713:0.012508:0.012450:0.011699:0.005792:0.005707:0.012508:0.011738:0.006523:0.005330:0.012604:0.005775:0.005330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.007466:0.013123:0.011699:0.013143:0.018049:0.012604:0.011699:0.007466:0.005330:0.012450:0.012508:0.003848:0.003848:0.005330
carcinoma of the head and neck with :@0.115151:0.812102:0.478044:0.812102:0.478044:0.796346:0.115151:0.796346:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.012604:0.006042:0.005330:0.006523:0.011738:0.012508:0.005330:0.011738:0.012508:0.013143:0.013181:0.005330:0.013143:0.011738:0.013181:0.005330:0.011738:0.012508:0.012450:0.009660:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330
disease progression on or after a :@0.115151:0.827541:0.422874:0.827541:0.422874:0.811785:0.115151:0.811785:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.013123:0.005723:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.012604:0.011738:0.005330:0.012604:0.005792:0.005330:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330:0.013143:0.005330
platinum-based therapy:@0.115151:0.842979:0.341404:0.842979:0.341404:0.827223:0.115151:0.827223:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388:0.013123:0.013143:0.007466:0.012508:0.013181:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
n :@0.084848:0.855907:0.098177:0.855907:0.098177:0.847467:0.084848:0.847467:0.009762:0.003566
 :@0.115149:0.855907:0.118715:0.855907:0.118715:0.847467:0.115149:0.847467:0.003566
locally advanced or metastatic :@0.115151:0.859026:0.415100:0.859026:0.415100:0.843270:0.115151:0.843270:0.003848:0.012604:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330:0.013143:0.013181:0.010660:0.013158:0.011738:0.012450:0.012508:0.013181:0.005330:0.012604:0.005792:0.005330:0.018049:0.012508:0.006523:0.013125:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330
urothelial carcinoma in patients who::@0.115151:0.874464:0.461145:0.874464:0.461145:0.858708:0.115151:0.858708:0.011699:0.005711:0.012604:0.006523:0.011738:0.012508:0.003848:0.003848:0.013143:0.003848:0.005330:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.003848:0.011738:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.011738:0.012604:0.005330
 :@0.084845:0.889903:0.090175:0.889903:0.090175:0.874147:0.084845:0.874147:0.005330
 –   have disease progression during or :@0.115148:0.889903:0.473607:0.889903:0.473607:0.874147:0.115148:0.874147:0.000000:0.009621:0.005330:0.015352:0.000000:0.011738:0.013143:0.010660:0.012508:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.013123:0.005713:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.013181:0.011699:0.005792:0.003848:0.011738:0.012950:0.005330:0.012604:0.005792:0.005330
following platinum-containing :@0.145458:0.905341:0.428533:0.905341:0.428533:0.889585:0.145458:0.889585:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330
chemotherapy:@0.145458:0.920780:0.285947:0.920780:0.285947:0.905024:0.145458:0.905024:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
 :@0.084845:0.936218:0.090175:0.936218:0.090175:0.920462:0.084845:0.920462:0.005330
 –   have disease progression within 12 :@0.115148:0.936218:0.471009:0.936218:0.471009:0.920462:0.115148:0.920462:0.000000:0.009621:0.005330:0.015352:0.000000:0.011738:0.013143:0.010660:0.012508:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.013123:0.005713:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.015990:0.003848:0.006523:0.011738:0.003848:0.011738:0.005330:0.010660:0.010660:0.005330
months of neoadjuvant or adju-:@0.584859:0.079471:0.880460:0.079471:0.880460:0.063715:0.584859:0.063715:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330:0.012604:0.006042:0.005330:0.011738:0.012508:0.012604:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.012604:0.005792:0.005330:0.013143:0.013181:0.003906:0.011661:0.006388
vant treatment with platinum-con-:@0.584859:0.094989:0.905764:0.094989:0.905764:0.079233:0.584859:0.079233:0.010660:0.013143:0.011738:0.006523:0.005330:0.006523:0.005707:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388:0.012450:0.012604:0.011726:0.006388
taining chemotherapy:@0.584859:0.110506:0.794466:0.110506:0.794466:0.094751:0.584859:0.094751:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
n :@0.524242:0.123376:0.537570:0.123376:0.537570:0.114936:0.524242:0.114936:0.009762:0.003566
 :@0.554542:0.123376:0.558108:0.123376:0.558108:0.114936:0.554542:0.114936:0.003566
adult and paediatric (12 years and :@0.554545:0.126495:0.886246:0.126495:0.886246:0.110739:0.554545:0.110739:0.013143:0.013181:0.011699:0.003848:0.006523:0.005330:0.013143:0.011738:0.013181:0.005330:0.013123:0.013143:0.012508:0.013181:0.003848:0.013143:0.006523:0.005792:0.003848:0.012450:0.005330:0.007100:0.010660:0.010660:0.005330:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330:0.013143:0.011738:0.013181:0.005330
older) patients with microsatellite :@0.554545:0.141867:0.866743:0.141867:0.866743:0.126111:0.554545:0.126111:0.012604:0.003848:0.013181:0.012508:0.005792:0.007100:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.018049:0.003848:0.012450:0.005705:0.012604:0.007466:0.013143:0.006523:0.012508:0.003848:0.003848:0.003848:0.006523:0.012508:0.005330
instability-high (MSI-H) or mismatch-:@0.554545:0.157240:0.882820:0.157240:0.882820:0.141484:0.554545:0.141484:0.003848:0.011738:0.007466:0.006523:0.013143:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.006388:0.011738:0.003848:0.012950:0.011738:0.005330:0.007100:0.017684:0.009583:0.004349:0.006388:0.013143:0.007100:0.005330:0.012604:0.005792:0.005330:0.018049:0.003848:0.007466:0.018049:0.013143:0.006523:0.012450:0.011738:0.006388
repair-deficient (dMMR) metastatic :@0.554545:0.172612:0.887783:0.172612:0.887783:0.156856:0.554545:0.156856:0.005713:0.012508:0.013123:0.013143:0.003848:0.005792:0.006388:0.013181:0.012508:0.004686:0.004686:0.012450:0.003848:0.012508:0.011738:0.006523:0.005330:0.007100:0.013181:0.017684:0.017684:0.011680:0.007100:0.005330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330
colorectal cancer that has progressed :@0.554545:0.187984:0.918438:0.187984:0.918438:0.172228:0.554545:0.172228:0.012450:0.012604:0.003848:0.012604:0.005707:0.012508:0.012450:0.006523:0.013143:0.003848:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.006523:0.011738:0.013143:0.006523:0.005330:0.011738:0.013143:0.007466:0.005330:0.013123:0.005694:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.005330
following treatment with a fluoropy-:@0.554545:0.203357:0.885555:0.203357:0.885555:0.187601:0.554545:0.187601:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.006523:0.005705:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.013143:0.005330:0.004666:0.004666:0.011699:0.012604:0.005688:0.012604:0.013123:0.010314:0.006388
rimidine, oxaliplatin, and irinotecan:@0.554545:0.218729:0.881166:0.218729:0.881166:0.202973:0.554545:0.202973:0.005792:0.003848:0.018049:0.003848:0.013181:0.003848:0.011738:0.012508:0.005330:0.005330:0.012604:0.009236:0.013143:0.003848:0.003848:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.005330:0.005330:0.013143:0.011738:0.013181:0.005330:0.003848:0.005792:0.003848:0.011738:0.012604:0.006523:0.012508:0.012450:0.013143:0.011738
n :@0.524242:0.231564:0.537570:0.231564:0.537570:0.223123:0.524242:0.223123:0.009762:0.003566
 :@0.554542:0.231564:0.558108:0.231564:0.558108:0.223123:0.554542:0.223123:0.003566
hepatocellular carcinoma in patients :@0.554545:0.234683:0.906181:0.234683:0.906181:0.218927:0.554545:0.218927:0.011738:0.012508:0.013123:0.013143:0.006523:0.012604:0.012450:0.012508:0.003848:0.003848:0.011699:0.003848:0.013143:0.005792:0.005330:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.003848:0.011738:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
who have been previously treated :@0.554545:0.250055:0.881323:0.250055:0.881323:0.234299:0.554545:0.234299:0.015990:0.011738:0.012604:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330:0.013123:0.012508:0.012508:0.011738:0.005330:0.013123:0.005698:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.003848:0.010314:0.005330:0.006523:0.005717:0.012508:0.013143:0.006523:0.012508:0.013181:0.005330
with sorafenib:@0.554545:0.265427:0.684239:0.265427:0.684239:0.249671:0.554545:0.249671:0.015990:0.003848:0.006523:0.011738:0.005330:0.007466:0.012604:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123
Atezolizumab:@0.524242:0.295610:0.664925:0.295610:0.664925:0.277589:0.524242:0.277589:0.015822:0.006414:0.013683:0.009835:0.013683:0.005131:0.005131:0.009835:0.012828:0.020098:0.014111:0.014111
Atezolizumab  is indicated for the treat-:@0.524242:0.313598:0.915157:0.313598:0.915157:0.297842:0.524242:0.297842:0.014239:0.006523:0.012508:0.008178:0.012604:0.003848:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.005330:0.006109:0.003848:0.007466:0.011449:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.011449:0.006042:0.012604:0.005792:0.011449:0.006523:0.011738:0.012508:0.011449:0.006523:0.005711:0.012508:0.013143:0.006523:0.006388
ment of::@0.524242:0.328970:0.602366:0.328970:0.602366:0.313214:0.524242:0.313214:0.018049:0.012508:0.011738:0.006523:0.005330:0.012604:0.006042:0.005330
135:@0.602348:0.323350:0.620993:0.323350:0.620993:0.314164:0.602348:0.314164:0.006215:0.006215:0.006215
n :@0.524242:0.341809:0.537570:0.341809:0.537570:0.333369:0.524242:0.333369:0.009762:0.003566
 :@0.554542:0.341809:0.558108:0.341809:0.558108:0.333369:0.554542:0.333369:0.003566
Locally advanced or metastatic :@0.554545:0.344928:0.859533:0.344928:0.859533:0.329172:0.554545:0.329172:0.008890:0.012604:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330:0.013143:0.013181:0.010674:0.013143:0.011738:0.012450:0.012508:0.013181:0.005330:0.012604:0.005792:0.005330:0.018049:0.012508:0.006523:0.013125:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330
urothelial carcinoma in patients who::@0.554545:0.360301:0.900539:0.360301:0.900539:0.344545:0.554545:0.344545:0.011699:0.005711:0.012604:0.006523:0.011738:0.012508:0.003848:0.003848:0.013143:0.003848:0.005330:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.003848:0.011738:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.011738:0.012604:0.005330
 :@0.524238:0.375673:0.529568:0.375673:0.529568:0.359917:0.524238:0.359917:0.005330
 –   are not eligible for cisplatin-:@0.554541:0.375673:0.841690:0.375673:0.841690:0.359917:0.554541:0.359917:0.000000:0.009621:0.005330:0.015352:0.000000:0.013143:0.005713:0.012508:0.005330:0.011738:0.012604:0.006523:0.005330:0.012488:0.003848:0.003848:0.012950:0.003848:0.013123:0.003848:0.012508:0.005330:0.006042:0.012604:0.005792:0.005330:0.012450:0.003848:0.007466:0.013123:0.003860:0.013143:0.006523:0.003848:0.011738:0.006388
containing chemotherapy, or:@0.584852:0.391045:0.860307:0.391045:0.860307:0.375289:0.584852:0.375289:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.012604:0.005792
 :@0.524238:0.406417:0.529568:0.406417:0.529568:0.390662:0.524238:0.390662:0.005330
 –   have disease progression during or :@0.554541:0.406417:0.913000:0.406417:0.913000:0.390662:0.554541:0.390662:0.000000:0.009621:0.005330:0.015352:0.000000:0.011738:0.013143:0.010660:0.012508:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.013123:0.005713:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.013181:0.011699:0.005792:0.003848:0.011738:0.012950:0.005330:0.012604:0.005792:0.005330
following any platinum-containing :@0.584852:0.421790:0.908451:0.421790:0.908451:0.406034:0.584852:0.406034:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.013143:0.011738:0.010314:0.005330:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330
chemotherapy, or within 12 months :@0.584852:0.437162:0.918842:0.437162:0.918842:0.421406:0.584852:0.421406:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.012604:0.005792:0.005330:0.015990:0.003848:0.006523:0.011738:0.003848:0.011738:0.005330:0.010660:0.010660:0.005330:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330
of neoadjuvant or adjuvant :@0.584852:0.452534:0.848049:0.452534:0.848049:0.436778:0.584852:0.436778:0.012604:0.006042:0.005330:0.011738:0.012508:0.012604:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.012604:0.005792:0.005330:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330
chemotherapy:@0.584852:0.467907:0.725341:0.467907:0.725341:0.452151:0.584852:0.452151:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
n :@0.524242:0.480740:0.537570:0.480740:0.537570:0.472299:0.524242:0.472299:0.009762:0.003566
 :@0.554542:0.480740:0.558108:0.480740:0.558108:0.472299:0.554542:0.472299:0.003566
Metastatic non-small-cell lung cancer :@0.554545:0.483859:0.911874:0.483859:0.911874:0.468103:0.554545:0.468103:0.017684:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.011738:0.012604:0.011738:0.006388:0.007466:0.018049:0.013143:0.003848:0.003848:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330:0.003848:0.011717:0.011738:0.012950:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330
in patients who have disease :@0.554545:0.499231:0.830154:0.499231:0.830154:0.483475:0.554545:0.483475:0.003848:0.011738:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.011738:0.012604:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330
progression during or following :@0.554545:0.514603:0.842671:0.514603:0.842671:0.498847:0.554545:0.498847:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.013181:0.011699:0.005792:0.003848:0.011738:0.012950:0.005330:0.012604:0.005792:0.005330:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330
platinum-containing chemotherapy. :@0.554545:0.529976:0.899965:0.529976:0.899965:0.514220:0.554545:0.514220:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330
Patients with EGFR or ALK genomic :@0.554545:0.545348:0.882917:0.545348:0.882917:0.529592:0.554545:0.529592:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.010314:0.016779:0.009333:0.011680:0.005330:0.012604:0.005792:0.005330:0.014239:0.008890:0.011372:0.005330:0.012950:0.012508:0.011738:0.012604:0.018049:0.003848:0.012450:0.005330
tumour aberrations should have :@0.554545:0.560720:0.856497:0.560720:0.856497:0.544964:0.554545:0.544964:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005330:0.013143:0.013123:0.012508:0.005792:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330
disease progression:@0.554545:0.576093:0.735730:0.576093:0.735730:0.560337:0.554545:0.560337:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.013123:0.005723:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738
Avelumab :@0.524242:0.606271:0.637986:0.606271:0.637986:0.588250:0.524242:0.588250:0.015822:0.011973:0.013683:0.005131:0.012828:0.020098:0.014111:0.014111:0.005987
Avelumab is indicated for  the  treatment :@0.524242:0.624259:0.920499:0.624259:0.920499:0.608503:0.524242:0.608503:0.012825:0.010660:0.012508:0.003848:0.011699:0.018049:0.013143:0.013123:0.008986:0.003848:0.007466:0.008986:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.008986:0.006042:0.012604:0.005792:0.005330:0.003641:0.006523:0.011738:0.012508:0.005330:0.003646:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
of::@0.524242:0.639631:0.548218:0.639631:0.548218:0.623876:0.524242:0.623876:0.012604:0.006042:0.005330
137:@0.548210:0.634012:0.566855:0.634012:0.566855:0.624826:0.548210:0.624826:0.006215:0.006215:0.006215
n :@0.524242:0.652471:0.537570:0.652471:0.537570:0.644031:0.524242:0.644031:0.009762:0.003566
 :@0.554542:0.652471:0.558108:0.652471:0.558108:0.644031:0.554542:0.644031:0.003566
metastatic Merkel cell carcinoma in :@0.554545:0.655590:0.894695:0.655590:0.894695:0.639834:0.554545:0.639834:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.017684:0.012508:0.005792:0.009660:0.012508:0.003848:0.005330:0.012450:0.012508:0.003848:0.003848:0.005330:0.012450:0.013143:0.005659:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.003848:0.011738:0.005330
adult and paediatric patients older :@0.554545:0.670962:0.888016:0.670962:0.888016:0.655206:0.554545:0.655206:0.013143:0.013181:0.011699:0.003848:0.006523:0.005330:0.013143:0.011738:0.013181:0.005330:0.013123:0.013143:0.012508:0.013181:0.003848:0.013143:0.006523:0.005792:0.003848:0.012450:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.012604:0.003848:0.013181:0.012508:0.005792:0.005330
than 12 years of age :@0.554545:0.686335:0.752126:0.686335:0.752126:0.670579:0.554545:0.670579:0.006523:0.011738:0.013143:0.011738:0.005330:0.010660:0.010660:0.005330:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330:0.012604:0.006042:0.005330:0.013143:0.012950:0.012508:0.005330
Durvalumab:@0.524242:0.716517:0.651242:0.716517:0.651242:0.698496:0.524242:0.698496:0.014966:0.012828:0.006842:0.011973:0.014111:0.005131:0.012828:0.020098:0.014111:0.014111
Durvalumab is indicated for the treatment :@0.524242:0.734505:0.920487:0.734505:0.920487:0.718749:0.524242:0.718749:0.014316:0.011699:0.005792:0.010660:0.013143:0.003848:0.011699:0.018049:0.013143:0.013123:0.005061:0.003848:0.007466:0.005061:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005061:0.006042:0.012604:0.005792:0.005045:0.006523:0.011738:0.012508:0.005049:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
of::@0.524242:0.749877:0.548218:0.749877:0.548218:0.734121:0.524242:0.734121:0.012604:0.006042:0.005330
138:@0.548210:0.744257:0.566855:0.744257:0.566855:0.735072:0.548210:0.735072:0.006215:0.006215:0.006215
n :@0.524242:0.762716:0.537570:0.762716:0.537570:0.754276:0.524242:0.754276:0.009762:0.003566
 :@0.554542:0.762716:0.558108:0.762716:0.558108:0.754276:0.554542:0.754276:0.003566
Locally advanced or metastatic :@0.554545:0.765836:0.859533:0.765836:0.859533:0.750080:0.554545:0.750080:0.008890:0.012604:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330:0.013143:0.013181:0.010674:0.013143:0.011738:0.012450:0.012508:0.013181:0.005330:0.012604:0.005792:0.005330:0.018049:0.012508:0.006523:0.013125:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330
urothelial carcinoma patients who::@0.554545:0.781208:0.879622:0.781208:0.879622:0.765452:0.554545:0.765452:0.011699:0.005711:0.012604:0.006523:0.011738:0.012508:0.003848:0.003848:0.013143:0.003848:0.005330:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.011738:0.012604:0.005330
 :@0.524238:0.796580:0.529568:0.796580:0.529568:0.780824:0.524238:0.780824:0.005330
 –   have disease progression during or :@0.554541:0.796580:0.913000:0.796580:0.913000:0.780824:0.554541:0.780824:0.000000:0.009621:0.005330:0.015352:0.000000:0.011738:0.013143:0.010660:0.012508:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.013123:0.005713:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.013181:0.011699:0.005792:0.003848:0.011738:0.012950:0.005330:0.012604:0.005792:0.005330
following platinum-containing :@0.584852:0.811952:0.867927:0.811952:0.867927:0.796196:0.584852:0.796196:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330
chemotherapy:@0.584852:0.827325:0.725341:0.827325:0.725341:0.811569:0.584852:0.811569:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
 :@0.524238:0.842697:0.529568:0.842697:0.529568:0.826941:0.524238:0.826941:0.005330
 –   have disease progression within 12 :@0.554541:0.842697:0.910402:0.842697:0.910402:0.826941:0.554541:0.826941:0.000000:0.009621:0.005330:0.015352:0.000000:0.011738:0.013143:0.010660:0.012508:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.013123:0.005713:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.015990:0.003848:0.006523:0.011738:0.003848:0.011738:0.005330:0.010660:0.010660:0.005330
months of neoadjuvant or :@0.584852:0.858069:0.832174:0.858069:0.832174:0.842313:0.584852:0.842313:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330:0.012604:0.006042:0.005330:0.011738:0.012508:0.012604:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.012604:0.005792:0.005330
adjuvant treatment with platinum-:@0.584852:0.873587:0.904507:0.873587:0.904507:0.857831:0.584852:0.857831:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.015990:0.003848:0.006508:0.011738:0.005330:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388
containing chemotherapy:@0.584852:0.889105:0.831251:0.889105:0.831251:0.873349:0.584852:0.873349:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
n :@0.524242:0.902088:0.537570:0.902088:0.537570:0.893648:0.524242:0.893648:0.009762:0.003566
 :@0.554542:0.902088:0.558108:0.902088:0.558108:0.893648:0.554542:0.893648:0.003566
Unresectable, stage III non-small-cell :@0.554545:0.905207:0.898809:0.905207:0.898809:0.889451:0.554545:0.889451:0.012604:0.011738:0.005709:0.012508:0.007466:0.012508:0.012450:0.006523:0.013143:0.013123:0.003848:0.012508:0.005330:0.005330:0.007466:0.006523:0.013143:0.012950:0.012508:0.005330:0.004349:0.004349:0.004349:0.005330:0.011738:0.012604:0.011722:0.006388:0.007466:0.018049:0.013143:0.003848:0.003848:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330
lung cancer patients whose disease :@0.554545:0.920725:0.894808:0.920725:0.894808:0.904969:0.554545:0.904969:0.003848:0.011699:0.011738:0.012950:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.011738:0.012604:0.007466:0.012508:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330
has not progressed following :@0.554545:0.936243:0.825765:0.936243:0.825765:0.920487:0.554545:0.920487:0.011738:0.013143:0.007466:0.005330:0.011738:0.012604:0.006523:0.005330:0.013123:0.005703:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.005330:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330
Biologicals:@0.795172:0.038601:0.914528:0.038601:0.914528:0.019343:0.795172:0.019343:0.013500:0.004704:0.015405:0.004704:0.015405:0.015828:0.004704:0.015216:0.016063:0.004704:0.009125